Naiyu Zheng
About Naiyu Zheng
Naiyu Zheng is the Scientific Associate Director at Bristol Myers Squibb, with over fifteen years of experience in regulated bioanalysis and significant contributions to drug development programs.
Current Role at Bristol Myers Squibb
Naiyu Zheng currently holds the position of Scientific Associate Director at Bristol Myers Squibb. Since August 2002, Zheng has been a part of the Department of Translational Medicine. In this capacity, Zheng has played a key role in the development and progression of several new drug development programs from the preclinical stage to clinical trials and first-in-human (FIH) studies.
Previous Experience at University of Pennsylvania School of Medicine
Naiyu Zheng served as a Postdoc Research Fellow at the University of Pennsylvania School of Medicine from 1999 to 2002. During the three-year tenure in Philadelphia, PA, Zheng conducted research under the guidance of Dr. Ian A. Blair, contributing to various scientific research projects within the field of pharmaceutical sciences.
Educational Background
Naiyu Zheng has a robust educational background with degrees from esteemed institutions. Zheng earned a PhD in Pharmaceutical Sciences from the University of Rhode Island between 1993 and 1999. Prior to that, Zheng received a Master of Science (MS) in Marine Organic Chemistry from the Institute of Oceanology, Chinese Academy of Sciences. Zheng's academic journey began with a Bachelor of Science (BS) in Analytical Chemistry from Xiamen University.
Expertise in Bioanalysis
With over fifteen years of experience, Naiyu Zheng is an expert in regulated bioanalysis of small molecule drugs, protein biotherapeutics, and biomarkers. Zheng has developed new bioanalytical strategies that enhance assay selectivity, sensitivity, and speed. Notable technologies employed include LC-MS bioanalysis for various biological matrices and the application of UHPLC with AMS, LC-HRMS, and hybrid LBA-LC-MS technologies for tackling bioanalytical challenges.
Contributions to Drug Development
Naiyu Zheng has significantly contributed to the advancement of Bristol Myers Squibb's drug pipeline. Zheng has had a hand in the development of several marketed drugs, including ABILIFY® (aripiprazole), ELIQUIS® (apixaban), and a series of HCV inhibitors which include DAKLINZA™ (daclatasvir), SUNVEPRA® (Asunaprevir), and Beclabuvir. Zheng’s work has been pivotal from preclinical stages through to clinical phases and first-in-human studies.